arrow
S

S. V. Morant

Pfizer
H指数:40
被引数:6,500

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Effect of timed dosing of usual antihypertensives according to patient chronotype on cardiovascular outcomes: the Chronotype sub-study cohort of the Treatment in Morning versus Evening (TIME) study

根据患者时间类型定时给药常规抗高血压药对心血管结局的影响: 早晚 (TIME) 治疗的时间类型亚研究队列

2024-06-012
OAAI
Using trained dogs and organic semi-conducting sensors to identify asymptomatic and mild SARS-CoV-2 infections: an observational study
2022-03-2417
OAAI
Impact of EU regulatory label changes for diclofenac in people with cardiovascular disease in four countries: Interrupted time series regression analysis
2020-08-0210
OAAI
Combination Therapy Is Superior to Sequential Monotherapy for the Initial Treatment of Hypertension: A Double-Blind Randomized Controlled Trial

高血压初始治疗联合治疗优于序贯单药治疗: 一项双盲随机对照试验

2017-11-0176
OAAI
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial

螺内酯与安慰剂,比索洛尔和多沙唑嗪的比较,以确定耐药性高血压的最佳治疗方法 (PATHWAY-2): 一项随机,双盲,交叉试验

LANCET
IF88.5
2015-11-01834
OAAI